Get started
Work

Effectiveness and Safety of Sofosbuvir-Based Regimens for Chronic HCV Genotype 3 Infection: Results of the HCV-TARGET Study

Year: 2020
Type: article
Abstract: Background. Sofosbuvir (SOF) is active against all hepatitis C virus (HCV) genotypes, and SOF-based therapies lead to high rates of sustained virologic response (SVR). However, genotype 3 (GT3) HCV remains a challenge with lower SVR rates reported, particularly in patients with cirrhosis. This study reports the effectiveness and safety of SOF-based therapy in patients with GT3 HCV treated in clinical practice.
DOI: 10.17615/b119-1877
Authors: Sterling, Richard, Schmidt, Monica, Zeuzem, Stefan, Akushevich, Lucy, Sherman, Ken, Maan, Raoel, Mailliard, Mark, Feld, Jordan J., Manns, Michael P., Fried, Michael W., Vainorius, Monika, Nelson, David R., Di Bisceglie, Adrian M., Frazier, Lynn M., Kuo, Alexander
Language: English
Subfield: Hepatology
Field: Medicine
Open Access status: green
OpenAlex ID: W4300438001
FWCI:
Cites:
Cited by:
Related to: 10